PetLife Seeks Investment for Investigational New Animal Drug Studies

Pharmaceutical Investing

PetLife Pharmaceuticals began offering a presentation to high net worth investors on the company’s mission of cancer in pets.

PetLife Pharmaceuticals (OTCQB:PTLF) began offering a presentation to high net worth investors on the company’s mission of cancer in pets.
As quoted in the press release:

While the presentations are targeted to high net worth investors, the Company has found that most of these investors share our passion for our furry friends. They understand our mission to bring an all-natural and cost-effective treatment of cancer through the necessary clinical trials and to make our patent pending product, VitalzulTM, an integral part of cancer treatment.
VitalzulTM is based on the venom of the Caribbean Blue Scorpion, which for hundreds of years has been known to have an effect on many varieties of tumors. Having completed several studies, PetLife is currently seeking funding to continue these pre-INAD (Investigational New Animal Drug) studies in preparation for a timely filing with the United States Food & Drug Administration (“FDA”) for a complete Oncology Clinical / Regulatory Development plan. The path through the FDA process is anticipated to take 18-24 months for completion.

Click here to read the full press release.

Source: www.accesswire.com

The Conversation (0)
×